Build my stack
Home · News · HHS peptide docket comments

HHS Peptide Policy Docket: Who Filed the 115 Published Comments, and What They Asked

The short version, read on 17 November 2026, 12:25 UTC

  • 289 comments received, 115 published. Regulations.gov counts 289 comments received on docket HHS-OASH-2026-0496 and shows 115. Every published comment was received between 30 October 2026 and 6 November 2026; nothing sent in the last week of the period, which closed on 13 November 2026, is public yet.
  • 104 of the 115 are one shared letter. It thanks HHS and urges it "to build on this progress by reconsidering excluded peptides, particularly thymosin alpha-1 (Ta1), as well as kisspeptin-10 and ipamorelin". 101 copies are word for word; the other 3 differ by a few words or lines. 94 of the 104 were received on 5 November 2026. The filings do not say who wrote the letter.
  • 2 ask HHS to withdraw the policy. Both are from private individuals. The other 113 do not ask for withdrawal.
  • 4 come from businesses: a testing start-up, a telehealth service, a compounding pharmacy and a men's health clinic. None asks for withdrawal.
  • None of the 115 is filed by a medical society, pharmacy board, state agency, trade group or drug maker, or by anyone writing as a public official. The Alliance for Pharmacy Compounding and the National Community Pharmacists Association have posted on their own site a joint letter to the docket dated 13 November; it is not among the published comments yet.

On 30 October 2026 HHS published an interim policy saying it does not intend to take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians that compound BPC-157, epitalon, KPV, MOTS-c, semax or TB-500 under ten conditions (91 FR 68526). The public could comment on regulations.gov, docket HHS-OASH-2026-0496, until 11:59 pm Eastern on 13 November 2026. Our reading of the policy itself: HHS published its peptide compounding policy.

The desk opened every published comment, and the one attachment among them, on regulations.gov, one by one, on 17 November 2026, 12:09 to 12:19 UTC, and sorted each by who filed it and what it asks HHS to do. Organisations are named, with their own words and a link to the comment. Private individuals are counted, not named. The full list of comments, by position, is at the foot of the page and in the CSV.

What the docket shows

What the comment asksCommentsFrom organisationsFrom individuals
Keep the policy and add excluded peptides (one shared letter)1040104
Keep the policy633
Allow more than the policy does202
Clarify its legal standing (says it does not oppose)110
Withdraw the policy202
Total published1154111

Counts read on 17 November 2026, 12:25 UTC. A comment is counted once, under the main thing it asks for. "From organisations" counts the four business filings below, including one filed under its owner's name and signed with the clinic's name.

The four organisations, in their own words

Filed byPositionWhat it asks HHS to doIn its wordsSource
VeritaPep
Describes itself as "a Florida company being formed to provide independent third party analytical verification of peptide products"
Keep the policyKeep the certificate of analysis and traceability conditions; make each certificate lot specific, naming the lab, methods and limits; say compounders may rely on independent testing as well as the maker's certificate."We ask HHS to keep the COA and traceability conditions at the center of the interim policy"Comment 0004, received 30 October 2026
MyRx Source
Describes itself as "a self-pay telehealth service"; filed by a cofounder
Keep the policyKeep the policy until FDA finishes 503A bulks list rulemaking for each peptide; state what would trigger narrowing or withdrawal and give notice first; confirm separately compounded single-ingredient products may be prescribed together; publish testing criteria, a model certificate and a way to verify bulk suppliers."keep the policy in effect until FDA completes 503A bulks list rulemaking for each peptide"Comment 0006, received 1 November 2026
Madison Medical Compounding Pharmacy (Mississippi)
Describes itself as "a state-licensed 503A pharmacy"
Clarify its legal standing (says it does not oppose)Clarify the policy's legal status under Section 503A; speed up the 503A bulks list decisions and publish a timeline; work with state boards. It cites the Mississippi Board of Pharmacy."Federal enforcement discretion does not necessarily establish legal authorization under Section 503A or protect pharmacies from state regulatory action."Comment 0008, received 1 November 2026
Spartan Elite (Tennessee)
A men's health clinic; filed by its owner, who writes as a clinician
Keep the policyAdopt the policy as drafted, and complete the underlying 503A rulemaking."I urge HHS to adopt it as drafted."Comment 0115, received 6 November 2026

The shared letter (104 comments)

104 comments carry the same text, filed under different names. It opens: "Thank you for advancing a policy to expand access to six compounded peptides." It asks HHS to "publish the criteria used to select peptides for this policy" and to explain how they were applied to excluded substances, and it names thymosin alpha-1, kisspeptin-10 and ipamorelin. Three copies differ: one is filed by two people and reads "We urge" in place of "I urge", one adds lines about the thymus and cancer, and one adds lines about friends and family who used peptides.

The two that ask for withdrawal

Both are from private individuals. One reads "I strongly urge you to scrap this proposed policy." (comment 0005). The other reads "I request withdrawal of this policy pending completed scientific review and the applicable regulatory process." and attaches an 11-page legal memorandum (comment 0010).

Other asks that recur

  • Blends and combinations. The policy allows one active ingredient per product. One individual objects: "By not allowing blends, you're forcing more prescriptions" (comment 0007). MyRx Source asks HHS to confirm that separately compounded products may be prescribed together.
  • Sale without a prescription. One anonymous comment asks for a lower-cost model alongside quality rules: "purchase more like vitamins, with an age-verification check at purchase" (comment 0003).
  • State law. Madison Medical Compounding Pharmacy says a pharmacy could meet every condition and still face its state board, and writes: "Our concern is not opposition to the interim policy."
  • Testing. VeritaPep and MyRx Source both ask for published testing criteria or lot-specific certificates. The policy's own testing conditions are set out on our policy page.

What is not in the table, and why

  • The 174 comments not yet published. Regulations.gov counts 289 received and shows 115. The agency decides when and whether to post each one, and the last published comment was posted on 6 November 2026. This page counts only what is public; we will read the rest when it is posted and date the update here.
  • The APC and NCPA letter. The Alliance for Pharmacy Compounding and the National Community Pharmacists Association published their joint comment, dated 13 November 2026, on APC's site. It supports the pathway and asks that, "for an initial, defined transition period, 503A pharmacies be required to obtain the covered APIs through FDA-registered U.S. repackagers or relabelers"; APC suggests one year, subject to review. It is not in the counts above because it is not yet published on the docket; it will be counted when it is.
  • Names of private individuals. They are public on regulations.gov, but this page counts them by position only. Each comment can be opened from the list below.
  • Statements made outside the docket. The American Medical Association's 9 November policy and the Partnership for Safe Medicines petition to the FDA (docket FDA-2026-P-13366) are not comments on this docket. Both are covered on our policy page.
  • Whether the comments are right. The desk sorted what each comment asks for. It did not test the claims made in them.
  • Who organised the shared letter. None of the 104 copies says, so neither do we.

Every published comment, by position

Each number opens the comment on regulations.gov (HHS-OASH-2026-0496-0003 to -0117; -0001 and -0002 are HHS's own documents).

Download

  • Docket comments, CSV (comment ID, link, received and posted dates, filer type, organisation where one filed, position, whether it is the shared letter). Private individuals are not named in it.

How to cite this page

The table and CSV are published under a Creative Commons Attribution 4.0 licence: you may reproduce, chart or adapt them with credit to Peptide Bureau and a link to this page. Suggested citation:

Peptide Bureau, "HHS Peptide Policy Docket: Who Filed the 115 Published Comments, and What They Asked," read 17 November 2026, https://peptidebureau.com/hhs-peptide-policy-docket-comments.html

The address above will not change when the count is updated. For any single comment, cite the comment itself on regulations.gov as well.

Corrections

If a count, a position or a quote here is wrong, email [email protected] with the comment number. Corrections are dated on this page.

This page reports public comments on a federal docket. It is not legal or medical advice, and a comment is the view of whoever filed it. None of the six peptides is an FDA-approved drug, and the policy is not an approval.

PB
The Peptide Bureau editorial desk. Peptide Bureau is a small independent research team covering peptide dosing, safety and vendors. We are not clinicians; nothing here is medical advice. How the Bureau works.

Disclosure: Peptide Bureau is funded by affiliate commission from research peptide stores. None of the organisations on this page is a partner, and this page carries no affiliate links or codes.